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Rift Valley fever (RVF) is a zoonotic disease that causes severe epizootics in ruminants, characterized by
mass abortion and high mortality rates in younger animals. The development of a reliable challenge
model is an important prerequisite for evaluation of existing and novel vaccines. A study aimed at
comparing the pathogenesis of RVF virus infection in US sheep using two genetically different wild type
strains of the virus (SA01-1322 and Kenya-128B-15) was performed. A group of sheep was inoculated
with both strains and all infected sheep manifested early-onset viremia accompanied by a transient
increase in temperatures. The Kenya-128B-15 strain manifested higher virulence compared to SA01-1322
by inducing more severe liver damage, and longer and higher viremia. Genome sequence analysis
revealed sequence variations between the two isolates, which potentially could account for the observed
phenotypic differences. We conclude that Kenya-128B-15 sheep infection represents a good and virulent
challenge model for RVF.
& 2015 Elsevier Inc. All rights reserved.Introduction
Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic
pathogen within the genus Phlebovirus, family Bunyaviridae.
Although large outbreaks have predominantly occurred in sub-
Saharan Africa, recent outbreaks outside of the African continent,
in the Arabian Peninsula, have raised concerns about the potential
spread of the virus to Europe, Asia and the Americas (Balkhy and
Memish, 2003; Bird et al., 2009; Chevalier et al., 2010; Pepin and
Tordo, 2010). Human infections with RVFV are associated with
acute febrile illness that in some cases can progress to more severe
disease, including retinal vasculitis resulting in blindness, ence-
phalitis and hepatitis resulting in fatal hemorrhagic fever (Bird
et al., 2009). Case fatality rates as high as 20–50% have been
reported (Heald, 2012; Nguku et al., 2010). In sheep, goats and
cattle, the disease is characterized by abortion storms and high
rates of mortality in young animals (Coetzer, 1977, 1982; Pepin and
Tordo, 2010). Due to concerns about its potential use as a biological
weapon, RVFV is categorized as a high priority agent by the
National Institute for Allergy and Infectious Diseases (NIAID),
Centers for Disease Control and Prevention (CDC) and the U.S.
Department of Agriculture (USDA).Because of the presence of experimentally proven competent
vectors, there is a high risk for introduction and establishment of
RVFV in the US (Iranpour et al., 2011; Turell et al., 2008, 2010).
Currently, there are no fully licensed RVFV vaccines in the US for
either livestock or human use. Therefore, development of an effec-
tive vaccine represents an important area of research and availability
of a challenge model is an important prerequisite for the develop-
ment, evaluation, and licensing of future vaccines. To date, several
RVFV animal infection models have been described in non-human
primates (Miller et al., 2002; Smith et al., 2012), mice (Busquets et
al., 2014; Flick and Bouloy, 2005; Ikegami and Makino, 2011; Linden
et al., 2015; Smith et al., 2010; Tomori and Kasali, 1979), hamsters
and rats (Easterday, 1965; Findlay, 1932; Flick and Bouloy, 2005;
Linden et al., 2015; Miller et al., 2002), and more recently in sheep
and goats (Busquets et al., 2010; Weingartl et al., 2014). Also, two
types of challenge models have been employed for vaccine efﬁcacy
studies: the pregnancy model, which requires effective synchroni-
zation of pregnancy in host species (Bird et al., 2011), and the vir-
emia model, which is affected by lack of consistency due to variation
in individual host animal responses (Drolet et al., 2012; Fagbami et
al., 1975; Kortekaas et al., 2012). Ideally, the development of an RVF
vaccine designed for use in livestock should be tested in its natural
host species, i.e. in ruminant livestock. Although sheep are the
livestock most susceptible to RVFV infection, there is lack of detailed
information about the impact of various sheep breed differences on
clinical responses to experimental RVFV infection, data which are
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sheep and goats was recently described (Weingartl et al., 2014). In
these studies, different breeds of sheep (Suffolk cross, Rideau Arcott
cross, Ile-de-France cross with Rideau Arcott) were inoculated with
a RVFV strain (ZH501) isolated in 1977 in Egypt. These and other
authors found that the clinical and pathological outcome of
experimental RVFV infections in ruminants is very much dependent
on the strain of RVFV used for inoculation, the species, breed and
age of the host animals.
Different strains of RVFV have been responsible for numerous
disease outbreaks in Africa and in the Arabian Peninsula. The
Kenya-128B-15 (Ken06) strain was isolated from a mosquito during
the Kenya 2006/2007 outbreak, which resulted in signiﬁcant
human and livestock mortalities (Sang et al., 2010). The SA01-1322
(SA01) strain was isolated from a mosquito during the Saudi Arabia
2000/2001 outbreak (Miller et al., 2002), which resulted in more
than 200 human deaths and signiﬁcant loss of livestock (Al-Hazmi
et al., 2003; Arishi et al., 2000; Madani et al., 2003). These strains
represent distinct genetic isolates and we hypothesized that they
would have phenotypic differences with different clinical and
pathological outcomes in infected susceptible livestock.
The aim of this study was to compare sheep infection with two
strains of RVFV, Ken06 and SA01, in order to obtain relevant clinical and
pathological data for subsequent evaluation of experimental vaccines.
Here we describe the establishment of a small ruminant challenge
model for RVF using sheep and two genetically distinct RVFV strains.Results
Rectal temperatures
In the ﬁrst study in Dorper x Katahdin sheep inoculated with
1106 PFU of SA01 or Ken06 rectal temperatures were measuredFig. 1. Kinetics of rectal temperatures of sheep inoculated with RVFV SA01 and Ken06
temperatures of SA01 and Ken06 inoculated sheep are signiﬁcantly higher than mock ino
geometric mean AST values for the different groups of sheep inoculated with the two dif
signiﬁcantly different from SA01 or mock-inoculated sheep (Po0.001), (D) shows percen
(n¼5) inoculated with 2106 pfu of Ken06;taken daily on 0–10, 14 and 21 days post infection (dpi). Rectal
temperatures showed transient increases from baseline with the
highest increase for both experimental groups (Ken06 and SA01)
occurring at 2 dpi (Fig. 1A). There were signiﬁcant differences in
mean rectal temperatures between baseline, 0 dpi (SA01¼39.8 °C,
Ken06¼39.7 °C, n¼6) and 2 dpi (SA01¼40.8 °C, Ken06¼41.1 °C,
n¼6) for animals inoculated with either RVFV strains (Po0.05). No
signiﬁcant change from baseline occurred in the mock-inoculated
control group (n¼2) during the length of the study. Also the
observed mean temperature differences between the virus inocu-
lated and mock- inoculated groups on 2 dpi were statistically sig-
niﬁcant (Po0.01). There was no signiﬁcant difference in mean
rectal temperatures between SA01 and Ken06 inoculated groups at
2 dpi (P40.05).
Polypay sheep (n¼5) inoculated with 2106 PFU of Ken06 in
the second study showed variable temperature responses (Fig. 1B).
Peak temperatures were observed on 1 or 2 dpi (range¼40.1–
41.9 °C), with an increase in all sheep (n¼4), except for sheep #45,
which showed an unusual decline in temperature from 1 to 3 dpi
then increase at 4 dpi. Three sheep, #41, #43 and #44, maintained
high temperatures (41.2 °C, 41.9 °C, 41.4 °C, respectively) at 2 dpi,
whereas sheep #42 had a lower temperature at 2 dpi. Thereafter,
animals showed transient increase and decrease in temperature
until 10 dpi, the study endpoint (Fig. 1B).Mortality
There was no mortality in the ﬁrst study in the Dorper x
Katahdin sheep. However, of the 5 Polypay sheep inoculated with
the higher dose of Ken06 virus, 3 animals (#41, #45, #44) died at
3, 4 and 5 dpi of acute RVFV infection.(A) and sheep inoculated with a higher dose of Ken06; nn denotes mean rectal
culated sheep (Po0.01), (B) GM¼group mean, (C) shows percentage change of the
ferent wild type strains of RVFV; nndenote AST values of Ken06 inoculated sheep are
tage change in individual AST and geometric mean (Geomean) AST values for sheep
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Analyses of blood chemistry values were performed for levels
of albumin, ALP, GGT, AST and BUN. No signiﬁcant changes in the
levels of albumin, ALP and GGT following viral inoculation were
found and consequently description of the analyses focused on the
levels of AST and BUN, as they appeared to be the most affected by
RVFV infection. Increased AST levels are indicative of hepatocel-
lular damage while BUN increases are associated with renal
damage. The AST levels were measured on day 0 through day
10 pi. In the ﬁrst study, a dramatic increase in mean percentage
change of enzyme level was observed for the Ken06 inoculated
group at 3 dpi followed by a steady decrease beginning at day
4 dpi to normal or near normal baseline levels by 10 dpi (Fig. 1C).
The SA01 inoculated group showed a slight but non-signiﬁcant
increase at 3 dpi compared to the mock inoculated control group
(P40.05). The mean percent changes in the AST levels were sig-
niﬁcantly higher in animals inoculated with Ken06 compared to
those inoculated with SA01 or the control group (Po0.001). The
Ken06 strain induced a peak mean increase at 3 dpi of 1059% in
the inoculated animals, whereas SA01 only induced a peak mean
increase of 160%; the control animals remained statistically
unchanged (Fig. 1C). Of the 5 sheep inoculated with the higher
dose of Ken06, 3 sheep (#41, #44, #45) responded with a more
dramatic elevation of AST levels (Fig. 1D). Interestingly, all of these
sheep with a dramatic AST increase were found dead within 1–2
days after its observation. The BUN concentrations were tested on
0, 3, 4, 5, 6 and 10 dpi and showed a peak level for both viruses at
3 dpi. The mean concentrations at 3 dpi, 5 dpi, 6 dpi and 10 dpi
were signiﬁcantly higher than values at 0 dpi (baseline values,
Po0.05) for sheep inoculated with either strain of the virus. BUN
values of non-infected control animals did not change signiﬁcantly
(P¼0.451). The BUN concentrations returned to near baseline
levels by 10 dpi, the sampling endpoint. Similar kinetics for BUN
values were observed in sheep inoculated with the higher dose ofFig. 2. Virus titration and RNA levels in sheep sera. The mean with the range of Ct val
(D) represent mean Ct values and viral titers, respectively, obtained from serum of sheep
PCR, the Ct value for at least 2 of the 3 RVF genome segments must be less than or equKen06 strain (data not shown). The mean WBC levels varied when
compared with baseline but no signiﬁcant trends increases or
decreases in virus inoculated animals were found (data not
shown).
Viremia
Virus was detectable in the serum starting at 1 dpi by both real-
time RT-PCR (Fig. 2A) and virus plaque assay (Fig. 2B). By 2 dpi, all
virus-inoculated sheep were viremic (Fig. 2A and B). Peak viremia
determined by virus titration occurred in sheep infected with
Ken06 at 2 and 3 dpi (Fig. 2B). Peak viremia for SA01 sheep
occurred at 2 dpi (Fig. 2B). Sheep infected with the SA01 strain
were all negative by both real-time RT-PCR (Fig. 2A) and plaque
assay by 5 dpi (Fig. 2B). Sheep inoculated with the Ken06 strain
were negative by real-time RT-PCR (Fig. 2A) at 7 dpi and by plaque
assay (Fig. 2B) at 6 dpi. Control sheep sera remained negative for
virus-speciﬁc markers throughout the study. In the follow up
study with 5 Polypay sheep inoculated with a higher dose of the
Ken06 strain, similar viral kinetics were observed with peak vir-
emia of sheep at 2 dpi (Fig. 2C and D). These results were con-
sistent with the ﬁrst study except Ct values at 3 dpi were slightly
lower (Fig. 2C–D).
Viral load or titers in tissues
In the virus comparison study, brain, liver, spleen and bile
samples collected at necropsy were tested for virus presence by
virus isolation. Ken06 was isolated from the liver at 3 and 4 dpi
(Fig. 3B), and from the spleen from 3 out to 21 dpi (Fig. 3D). SA01
was isolated from the liver at 3 dpi (Fig. 3B), and from the spleen at
3, 5 and 6 dpi (Fig. 3D). Virus isolation at 3 and 4 dpi in liver and
spleen correlated with the low Ct values detected in the liver and
spleen tissues of Ken06 infected sheep on the same days by RT-
PCR (Fig. 3A and C). No virus was isolated from the brain or bileues (A) or viral titers (B) for virus positive sheep serum are shown. Panel (C) and
inoculated with the higher dose of Ken06. To be considered positive by real-time RT-
al to 35 (represented by a dashed line).
Fig. 3. Virus titrations and RNA levels of various tissues after RVFV infection. Mean Ct values obtained from liver tissue samples (A) and virus titers obtained from the liver
(B) of sheep inoculated with SA01 and Ken06; mean Ct values for spleen tissue samples (C) and virus titers obtained from the spleen (D). Bottom panels showmean Ct values
for liver and spleen tissue samples (E) and virus titers of isolates from the liver and spleen (F) of sheep inoculated with the higher dose of Ken06 strain. Necropsies were not
performed on days 0, 1, 2 or 7 post inoculation (N/A).
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pled from the control sheep. All nasal swabs collected from sheep
inoculated with the SA01 strain were negative by RT-PCR. At 4 dpi
low levels (o2 log10 pfu/ml) of virus were isolated from the nasal
swabs of 3 out of the 6 sheep infected with the Ken06 strain. In the
later study with the higher dose of Ken06 strain, virus was isolated
from the liver and spleen (Fig. 3F) of inoculated sheep at 3, 4 and
5 dpi. Higher viral titers in both tissues were observed. No nasal
swabs were collected during the second, Ken06 only, study.
Serological responses
ELISA serologic responses are presented in Fig. 4. In the ﬁrst
study, sera obtained from animals in both experimental groups,
SA01 and Ken06, had increased antibody activity against the RVFV
N and Gn proteins as indicated by ELISA from 5 to 21 dpi (Fig. 4A
and B). The overall trend showed a time-dependent increase in the
level of total IgG response with peak responses occurring at 21 dpi(Fig. 4A and B). N-speciﬁc antibody responses had higher OD
values compared to the Gn-speciﬁc responses (Fig. 4A and B). In
the Ken06 only study, onset of seroconversion as measured by IgG
response in the N-speciﬁc ELISA was at 5 dpi, with a time-
dependent increasing antibody response until study endpoint at
10 dpi. Seroconversion in the Gn-speciﬁc ELISA was detected at
10 dpi. The non-vaccinated sheep did not seroconvert (Fig. 4C).
Results of the plaque reduction neutralization assay for the ﬁrst
study are shown in Table 1. Three (3) out of 6 animals in the SA01-
infected group and 4 out of 6 in the Ken06-infected group had
detectable neutralizing antibody titers (titer¼10) at 3 dpi; one
animal inoculated with Ken06 developed a detectable neutralizing
titer at 2 dpi. At 4 dpi, 4 out of 5 animals inoculated with SA01 and
Ken06 developed mean neutralizing antibody titers of 15 and 20,
respectively (Table 1). All virus inoculated sheep developed neu-
tralizing antibody titers by 5 dpi. The neutralizing antibody titers
increased steadily through 21 dpi for all animals reaching titration
end point levels (titer¼1280) at 9 dpi for the Ken06-infected
Fig. 4. Speciﬁc indirect ELISA shows kinetics of total IgG antibody responses in sheep inoculated with wild type RVFV strains, SA01 (A) (cut-off for Gn-ELISA¼0.308,
N-ELISA¼0.321) and Ken06 (B) (cut-off for Gn-ELISA¼0.239; N-ELISA¼0.483), C shows responses in non-infected control sheep, D shows IgG responses in sheep inoculated
with increased dose (2106) of Ken06 strain (cut-off for Gn-ELISA¼0.14, N-ELISA 0.192).
Table 1
Reciprocal PRNT80 titers in sheep infected with RVFV strains, SA01 and Ken06.
Reciprocal PRNT80 titers
Sheep no.
Virus strain Days: 0 preinf 1 pi 2 pi 3 pi 4 pi 5 pi 6 pi 7 pi 8 pi 9 pi 10 pi 14 pi 21 pi
54 SA01    10
65 SA01     10 20 80
58 SA01      40
59 SA01     10 40 80
60 SA01    10 20 80 160 640 640 320 1280
61 SA01    10 20 80 80 160 320 1280 41280 41280 41280
Mean 10a 15b 52 100 400 480 800 1280 1280 1280
63 Ken06    
62 Ken06    10 10
64 Ken06    10 20 40
55 Ken06    10 10
68 Ken06      40 80 80 640 1280 41280
69 Ken06   10 10 40 80 320 1280 41280 41280 41280 41280 1280
Mean 10b 20b 53 200 680 960 1280 1280 1280 1280
Key:
preinf¼pre-infection; pi¼post infection; the blanks for individual animals at the various days pi signify the animals were euthanized before this time point; () indicates no
neutralizing antibody titers were detected.
a n¼3
b n¼4
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were maintained in both groups until 21 dpi, the study endpoint
(Table 1). Overall, the two different strains elicited similar kinetics
of neutralizing antibody response showing no statistically sig-
niﬁcant differences in the mean neutralizing antibody titers
between the two experimental groups (P40.05). The mock-
inoculated control sheep did not develop neutralizing antibody
titers. Two of the Polypay sheep inoculated with a higher dose of
Ken06 were tested for neutralizing antibody titers on 0, 5, 6, 7,
8 and 10 dpi. Overall, the neutralizing antibody response in thesheep showed similar time-dependent increases in titers, with
peak titers detected at 10 dpi, the study endpoint (Table 2).
Genome analysis
Genome sequence analysis of SA01 and Ken06 revealed
nucleotide and amino acid variations in the L, M and S segments.
The L, M and S segments of Ken06 showed 1.19% (76 mutations),
1.49% (58 mutations) and 1.54% (26 mutations) nucleotide varia-
tion, respectively, relative to SA01. At the amino level, in
B. Faburay et al. / Virology 489 (2016) 128–140 133comparison to SA01, Ken06 strain manifested 11 aa substitutions
(0.53% variation) in the L protein, 2 substitutions (1.31% variation)
in NSm, 8 substitutions (1.5% variation) in Gn, 2 (0.39% variation)
in Gc, and 5 (1.88% variation) in NSs proteins. The N protein was
highly conserved between the two strains manifesting no amino
acid differences. The two strains clustered in different genetic
clades in the phylogenetic tree (Fig. 5).
Pathology
In the ﬁrst study, comparing SA01 and Ken06, gross pathology
observations revealed no consistent pattern of differences
between the two virus strains. Necropsies at 3-4 dpi, had the most
prominent gross lesions. Livers were diffusely pale with pinpoint
tan foci consistent with necrosis disseminated throughout the
hepatic parenchyma (Fig. 6A). Animals necropsied on day 5 and
6 were similar to the earlier dpi time-points, although there were
decreased numbers of necrotic foci apparent throughout their
livers. Petechiae and ecchymoses were present in the hepatic
parenchyma some of the early time-point animals, but this was
not tied to a single strain or time-point. While gross lesions were
absent in livers at later post-infection time-points, livers remained
pale throughout the study. Mild splenomegaly was the only other
gross lesion attributable to RVFV.
Similar and frequently more severe gross lesions in the liver
were appreciated during the second Ken06 only study. The three
animals that died acutely had larger necrotic foci as well as mul-
tifocal hemorrhage (Fig. 6B). Again, spleen changes, splenomegaly
and additionally occasional subcapsular hemorrhages, were seen.
Lungs were heavy, wet and multifocally or nearly diffusely dark
pink, interpreted as pulmonary edema and congestion. No gross
lesions were appreciated at the 10 dpi necropsies in the
second study.
Hepatic histopathology scores and immunohistochemistry
(IHC) ﬁndings are summarized in Table 4 for the virus comparison
study and Table 5 for the second study. Hepatic histopathologic
changes were present on a background of mild peri-portal lym-
phoplasmacytic inﬂammation present in all study animals
including uninoculated controls (Fig. 7A and B). RVFV antigen IHC
was convincingly negative on uninoculated control liver and the
detection system exhibited minimal background (Fig. 7C and D)Table 2
Reciprocal PRNT80 titers in sheep inoculated with 2106 pfu of RVFV Ken06 strain.
Reciprocal PRNT80 titers
Sheep no.
Days: 0 preinf. 5 pi 6 pi 7 pi 8 pi 10 pi
42 0 80 80 320 640 1280
43 0 80 80 160 320 41280
Mean 80 80 240 480 1280
Key: preinf¼pre-infection; pi¼post infection.
Table 3
Liver histopathology score descriptions.
Histopathology Score Description
0 No lesions attributable to Rift Valley Fever virus
1 Multifocal, mid-zonal to central foci of lymphohistiocytic (lymph
occasional single hepatocyte necrosis
2 Multifocal, 1–2 mm areas of mid-zonal to central lymphohistioc
predominantly neutrophils. Less than 5% of examined parenchy
3 As prior but more severe necrotic lesions involving up to 15% o
3þ Greater than 15% of the parenchyma is necrotic and severe muIn the virus comparison study, regardless of virus strain and
dose, early time-point post-infection sheep livers had similar
hepatic histopathology. However, matched time-point Ken06
livers consistently labeled more strongly for RVFV antigen by IHC
than SA01 livers (Fig. 7E–L). Hepatic lesions were multifocal yet
spared the portal tracts and ranged from foci of predominantly
histiocytic inﬂammation to similar inﬂammation surrounding
necrotic foci ﬁlled with cellular debris as well as degenerate and
viable neutrophils. The most severe lesions were accompanied by
marked amounts of hemorrhage and ﬁbrin thrombi in central
veins immediately adjacent to foci of necrosis (Fig. 7 M and N).
Hepatic lesions in all acute time-point animals (3–5 dpi) contained
hepatocytes and macrophages whose cytoplasm was positive for
viral antigen (Fig. 7G,H, K,L and O,P). (Fig. 7M–P). In the virus
strain comparison study, there were no hepatic lesions attribu-
table to either virus strain by day 10 with the exception of SA01
animal #61, which had scattered single hepatocyte necrosis
accompanied by low numbers of macrophages, all negative for
RVFV by IHC. Likewise hepatic lesions were mild in the two ani-
mals in the second study that survived until study end point,
10 dpi.
Splenic changes in early time-point post-infection Ken06 ani-
mals in the virus comparison study differed from those in the SA01
animals. While lymphoid follicular hyperplasia as well as mild
scattered lymphoid follicle depletion was found in all early time-
point spleens compared to control animal tissues; the changes in
Ken06 animal spleens were more prominent. Additionally, 3 and
4 dpi Ken06 spleens had scattered perifollicular necrosis involving
the red pulp which was IHC positive for RVFV antigen. Both SA01
and Ken06 acute time-point animals had lymph node histiocytosis.
These lymphoid tissue changes were present and more severe in
the three acute time-point second study animals in which we
observed multifocal to diffuse lymphoid follicle depletion, red pulp
necrosis and ﬁbrin deposition in spleens as well as moderate to
marked lymphoid follicle depletion in mesenteric lymph nodes.
Multifocally, histiocytes in the sinusoids of these lymph nodes
were positive for viral antigen. In the second Ken06 only study,
kidney glomeruli often appeared hypercellular and were positive
for viral antigen. Similar glomerular changes were observed mul-
tifocally in a 4 dpi Ken06 animal in the virus comparison study.
Additionally, animal #43 in the second study, euthanatized at
10 dpi had multifocal renal tubular necrosis with adjacent lym-
phoplasmacytic interstitial nephritis. Affected tubular epithelial
cells and luminal debris were positive for viral antigen.
Additional lesions were appreciated in other organs. A Ken06
4 dpi animal in the virus comparison study had mild multifocal
adrenocortical necrosis in the zona fasciculata that was positive for
RVFV antigen. A 10 dpi SA01 and a 21 dpi Ken06 sheep in this
study also had occasional glial nodules in cerebral brain par-
enchyma. Additionally, one Ken06 10 dpi animal had multifocal
perivascular lymphohistiocytic inﬂammation in its brain stem.
None of these brain lesions were positive by IHC. Also in multiple
early time-point animals for both viral strains we observed small
cardiac lesions, i.e. foci of histiocytic and lymphoplasmacyticocytes and macrophages) inﬂammation with lesser numbers of plasma cells and
ytic inﬂammation frequently with central necrosis shifting inﬂammation to
ma involved
f hepatic tissue reviewed. Additionally present is scattered hepatocyte apoptosis.
ltifocal hemorrhage is also present
Nucleotide Substitution per 100 residues
0
3.2
2
RVFV-Ken-Gar131B06 (HM86972)
RVFV-KEN-KLF-07 (HM586973)
68.2
RVFV-Ken-Bar07(HM586968)
81.9
RVFV-M48-08-Madag (HQ009512)
NA
RVFV-Ken06-128B-15
41.5
RVFV-Tan 07 (HM86970)
61.9
RVFV-Sudan 2007 (JQ820490)
RVFV-Sudan 2010 (JQ820491)
99.8
100.0
RVFV-SA00 (DQ380197)
RVFV-SA01-1322
100.0
94.8
RVFV-KEN83 (DQ380198)
100.0
RVFV-Zinga (DQ380217)
100.0
RVFV-ZH501 (DQ380200)
RVFV-ZH548 (DQ380206)
100.0
Fig. 5. Phylogenetic analysis of nucleotide sequences of the M segments of various RVFV strains. The phylogenetic tree shows separation of Ken06 and SA01 (circled) into
separate clades indicating that the two strains are genetically distinct. NA¼not applicable.
Fig. 6. Gross liver pathology photos of acute post-infection time-point livers in situ from virus inoculated cattle were diffusely pale. (A) A virus comparison study animal
inoculated with Ken06 and euthanized at 3 dpi, additionally had multifocal 1 mm tan foci (necrosis) disseminated throughout the tissue, (B) the higher dose Ken06 study
animal #44 that died 5 days post-inoculation additionally had larger foci of necrosis white “’” and diffuse petechiation.
Table 4
Histopathology and immunohistochemistry for the SA01 and Ken06 comparison
study.
Sheep no. Virus strain Days PI Avg H Score IHC H Other Organs IHC þ
54 SA01 3 3 þ s 
58 SA01 5 2 þ h 
59 SA01 6 2  h 
65 SA01 6 1  h, 
60 SA01 10 0  i, b 
61 SA01 21 1.5  h 
63 Ken06 3 3 þ s s
62 Ken06 4 3 þ s, h s
55 Ken06 4 3 þ a s, a, k
64 Ken06 5 1 þ h 
68 Ken06 10 0  b, e 
69 Ken06 21 0  b 
70 Mock 21 0   
71 Mock 21 0   
Avg H Score is average hepatic histopathology score as per Table 3. IHC denotes "+"
or "–" liver IHC result. H Other Organs is histopathology in organs other than the
liver. IHC + denotes which additional tissues were positive for RVFV antigen. Key:
s¼spleen, h¼heart, i¼ intestine, b¼brain, a¼adrenal, e¼eye and k¼kidney.
B. Faburay et al. / Virology 489 (2016) 128–140134inﬂammation, that were negative for virus antigen by IHC and not
virus strain speciﬁc. One Ken06 10 dpi animal had aggregates of
macrophages and neutrophils in the iridocorneal angle of one eye
that were negative for viral antigen. However, we observed no eye
lesions in any other sheep including the second study animals. All
acute time-point 3-5 dpi second study sheep had multifocal pul-
monary edema as evidenced by increased numbers of intra-
alveolar macrophages. Finally, the 10 dpi SA01 sheep on thevirus comparison study had a prominent intestinal coccidiosis,
potentially enhanced by the stress of high containment housing.Discussion
Understanding the pathogenesis of RVFV infection in suscep-
tible hosts is a prerequisite for developing a reliable challenge
model for testing and evaluation of RVF vaccines. Previous studies
have focused on strain ZH501, isolated in 1977 in Egypt (Weingartl
et al., 2014). In this study, we examined the clinical and patholo-
gical outcome of experimental infection with two more recently
isolated genetically distinct strains of RVFV, SA01-1322 and Kenya
06-128B-15 (Miller et al., 2002; Sang et al., 2010) in the most
susceptible livestock species, the sheep. The results of this study
showed that Dorper x Katahdin cross and Polypay breeds of sheep
are susceptible to RVFV infection showing viremia upon infection
with either strain of the virus (Fig. 2B and D). The viremia induced
by both strains in sheep was transient, lasting on average 3 days,
with peak levels occurring at 2 and 3 dpi; this was consistent with
the gross and microscopic lesions and viral antigen presence in
organs.
The detection of viremia coincided with the appearance of
fever, at 2 and 3 dpi. Furthermore, virus was isolated from liver
and spleen of sheep infected with both strains at multiple time
points, from 1–5 dpi. Our overall ﬁndings demonstrate that both
viral strains induced RVFV clinical signs in both sheep breeds.
Viremia is a key metric for vaccine efﬁcacy and for determining
host susceptibility to RVFV infection (Bird et al., 2008, 2011;
Weingartl et al., 2014; Wilson et al., 2014). The ﬁndings in this
study suggest susceptibility of both breeds of sheep, Polypay and
B. Faburay et al. / Virology 489 (2016) 128–140 135the Dorper x Katahdin cross, to RVFV infection and their suitability
as an experimental animal for vaccine studies.
Regardless of virus strain and dose, early time-points post-
infection multifocal necrosis often accompanied by hemorrhage
(Fig. 6A and B) was found in the liver, consistent with gross hepatic
lesions reported prior from natural RVF cases in sheep (DaubneyTable 5
Histopathology and immunohistochemistry for the Ken06 only study.
Sheep no. Virus strain Days PI H Score IHC H Other Organs IHC þ
41 Ken06 3 died 3þ þ l, s, ln s, ln
45 Ken06 4 died 3þ þ l, s, ln s, ln, k
44 Ken06 5 died 3þ þ l, s, ln s, ln, k
42 Ken06 10 1  l, k 
43 Ken06 10 1  k k
Columns as described for Table 4. Key: þ¼positive for viral antigen by IHC,
¼negative for viral antigen on IHC, l¼ lung, s¼spleen, k¼kidney and ln¼me-
senteric lymph node. * Kidney was not available for animal #41. The liver histo-
pathology score for three of these animals was appreciably higher than a score of
3 in Table 3.
Fig. 7. Acute time-point liver histopathology and immunohistochemistry. (A) and (B) 10
animal. Each broken line box outlines the region shown at 400x magniﬁcation in the n
commonly seen in all animal’s hepatic portal tracts, (C) Rift Valley fever virus antigen IH
minimal on the no primary antibody reagent control slide for viral antigen immunohisto
seen in some central vein lumens. Row’s 2–4 in order left to right: 100x H&E, 400x H&E,
Row 3 is from a 3 dpi Ken06 inoculated sheep and Row 4 is a second study Ken06 inocula
hepatic necrosis with predominantly neutrophilic and histiocytic inﬂammation (E–F, I–J a
(M–N). Positive IHC signal in these lesions is the dark brown–red chromogen precipitat
debris (G–H, K–L, Q–P). The black arrows on (H) denote examples of IHC positive cells.and Garnham, 1931; Swanepoel and Coetzer, 1994). In both
experimental studies reported here, the hepatic histopathology
ﬁndings correlated well with the gross ﬁndings. The low numbers
of peri-portal lymphocytes and plasma cells additionally seen in all
livers including those of the uninoculated control animals were
negative for viral antigen by IHC and considered to be within nor-
mal limits for incidental peri-portal inﬂammation seen in normal
sheep (Fig. 7A–D). RVFV attributable lesions were multifocal yet
typically spared the portal tracts and ranged from foci of lympho-
histiocytic inﬂammation to similar inﬂammation surrounding
necrotic foci ﬁlled with cellular debris and degenerate and viable
neutrophils. The most severe lesions were accompanied by
hemorrhage (Fig. 7E–F, I–J and M–N). These lesions frequently
contained hepatocytes and macrophages whose cytoplasm was
positive for viral antigen (Fig. 7G–H, K–L, and O–P). On average, dpi
matched study animals had similar hepatic histopathology. How-
ever, the RVFV antigen IHC signal from the Ken06 samples was
consistently stronger in these time-point matched samples. Addi-
tionally, only Ken06 animals had RVFV IHC positive splenic lesions
at 3 and 4 dpi. Acute time-point higher dose Ken06 study animals
exhibited a marked increase in their degree of hepatic and splenic0x hematoxylin and eosin (H&E) stains of liver parenchyma from a mock inoculated
ext image In, (B) white “n” denotes lymphoplasmacytic background inﬂammation
C on mock inoculated animal control tissue was negative and (D) background was
chemistry (IHC), both 400x. The black star “n” in (C) denotes acid hematin (artifact)
IHC for viral antigen at 100x and 400x. Row 2 is from a 3 dpi SA01 inoculated sheep,
ted animal that died 4 dpi. Rift Valley fever virus caused acute mid-zonal to central
nd M–N). Additionally, hemorrhage was common within the larger necrosis lesions
e in the cytoplasm of hepatocytes, neutrophils and macrophages as well as cellular
Bars in columns 1 and 3 are 20 mm and bars in columns 2 and 4 are 50 mm.
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comparison to Ken06 animals in the ﬁrst study, attributable to
either the higher viral inoculum dose or change in sheep breed. The
second study animals also regularly had kidney changes, commonly
glomerular ﬁltration of RVFV antigen and less commonly scattered
tubular degeneration and necrosis. Greater understanding of these
kidney changes might be gained through additional special stains
and use of electron microscopy. The gross and histopathology
lesions that we found in both studies including changes in the
lymph nodes, adrenal gland, brain, heart and eye were consistent
with RVFV lesions reported prior for both natural disease cases in
sheep and experimental sheep RVFV inoculations (Daubney and
Garnham, 1931; Easterday, 1965; Ikegami and Makino, 2011; Swa-
nepoel and Coetzer, 1994; Rippy et al., 1992). Overall, the lesions
were more severe in time-point matched Ken06 animals and these
changes were heightened in the second study.
Similar temperature responses were observed in SA01 and
Ken06 inoculated sheep in the virus comparison study (Fig. 1A).
However, virus was isolated from nasal discharges of sheep
infected with Ken06 but not with SA01. Shedding of infectious
RVFV in nasal discharges of infected sheep has not been widely
documented in the scientiﬁc literature (Busquets et al., 2014;
Nicholas et al., 2014), and detection of the virus in the nasal dis-
charges of sheep inoculated with Ken06 could be an indication of
high virulence and upper respiratory tropism of this virus. Mock
inoculated control sheep housed alongside the challenged animals
remained negative throughout the study, suggesting the virus was
not shed at adequate levels for transmission to occur among the
sheep. Although RVFV is most often transmitted through infected
mosquito bites, the potential for transmission through nasal dis-
charge should not be entirely ruled out. However, in all of our
RVFV infection trials so far, we have not observed non-infected
control animals housed together with experimentally infected
animals becoming infected or seroconverting. Additional evidence
for higher virulence for Ken06 when compared to SA01 is the
detection of consistently higher percentage increases in AST levels
in animals inoculated with this strain (Fig. 1C and D). The increase
levels of this liver enzyme in the serum signiﬁes hepatocellular
damage in the affected animals (Smith et al., 2012), and the level
of increase may be indicative of the severity of the damage.
Additionally, 3 of the 5 Polypay sheep given the higher dose of
Ken06 died from acute RVFV infection following peak viremia,
with all animals showing dramatic increases in AST levels and
severe liver lesions. Increased BUN values in some of the animals
following infection are consistent with kidney involvement.
Importantly, RVFV antigenwas detected in the kidney of one sheep
inoculated with Ken06 in the virus comparison study and in sev-
eral kidneys from sheep in the higher dose study.
Genome sequence analysis revealed sequence differences
between the two challenge isolates, SA01 and Ken06. Notably,
sequences of the non-structural protein, NSs, were the most
variable between the two strains (see data in Results), which is
consistent with previous ﬁndings of high variability of this gene
among phleboviruses (Sall et al., 1997). Given the role of NSs as a
major virulence factor for RVFV (Bouloy et al., 2001; Billecocq et
al., 2004; Le May et al., 2008; Habjan et al., 2009; Ikegami et al.,
2009), variability within its amino acid sequences could possibly
account for the phenotypic differences between different virus
strains.
Sheep exposed to both viral strains manifested serological
responses to infection. The onset of seroconversion determined by
N-speciﬁc IgG antibody ELISA (Faburay et al., 2013; Paweska et al.,
2008a) was at 5 dpi in response to infection with both virus strains
(Fig. 4A, B and D). Overall, both N-speciﬁc and Gn-speciﬁc anti-
body responses manifested a similar trend of increasing titers over
time, although higher antibody activity was detected in the N-speciﬁc ELISA compared to the Gn-ELISA. These results corroborate
the ﬁndings of other studies that demonstrate early-onset and
strong antibody response to N protein upon RVFV infection (Fab-
uray et al., 2013; Jansen van Vuren et al., 2007; Paweska et al.,
2008b). The RVFV nucleocapsid protein is the most abundant viral
protein and considered a suitable diagnostic antigen for detecting
RVFV infection and monitoring vaccination with attenuated or
inactivated viruses (Faburay et al., 2014, 2013). Although the
majority of Dorper x Katahdin cross inoculated with either virus
developed neutralizing antibody titers at 3 dpi, titers correlating
with protection (Z1:40) (Pittman et al., 2000) were only detected
starting on 4 and 5 dpi, following appearance of acute clinical
symptoms (fever) and viremia regardless of breed. The induction
of neutralizing antibody response indicated host response to
experimental virulent infection, and with the increase in neu-
tralizing antibody titers over time (from 5 dpi onwards;
Tables 1 and 2) resulted in suppression of virus replication and
clearance of virus from the serum and tissues.
Although no infectious virus was detected in the serum of
surviving animals after 5 dpi (Fig. 2B and D), the occurrence of
viremia allows virus dissemination to peripheral organs, including
liver and spleen as observed in these studies; and virus could be
isolated from these tissues at 3–5 dpi (liver) and up to 21 dpi
(spleen) of Dorper x Katahdin crossbred sheep inoculated with
Ken06 (Fig. 3B, D and F). Isolation of low amounts of infectious
virus from the liver and spleen after 6 dpi was supported by
detection of viral nucleic acid in these tissues at the same time
period (Fig. 3C and D). This suggests that animals recovering from
virulent infection may harbor low levels of virus for an extended
period of time in tissues, especially in the spleen, further indi-
cating the utility of these tissues as useful diagnostic specimens
for the diagnosis of RVF and for vaccine studies. The isolation of
RVFV from organs and tissues of infected animals after appearance
of clinical symptoms poses some potential risk of contact con-
tamination, and could account for human (notably veterinarians
and abattoir workers) infections (Swanepoel and Coetzer, 1994).Conclusion
This is the ﬁrst study that compared the pathogenesis of two
genetically distinct virulent strains of RVFV (SA01 and Ken06) in a
ruminant model, the sheep. It also represents the ﬁrst study in a
ruminant challenge model to demonstrate a peracute form of RVF
caused by one of the wild type strains (Ken06). The ﬁndings sug-
gest that genetic diversity between strains of RVFV can manifest in
phenotypic differences. Sheep, the livestock species naturally most
susceptible to RVFV, represents a relevant large animal model for
RVF studies. The major clinical and pathological features, such as
viremia, fever, hepatitis and hepatic necrosis were consistently
reproduced in this host. Furthermore, this animal model could be
used to understand RVFV pathogenesis and RVFV-induced
pathology. The two genetically distinct viruses used in the pre-
sent study (Ken06 and SA01) showed phenotypic differences, with
Ken06 manifesting higher virulence in the Dorper x Katahdin
cross. Genome sequence analysis revealed signiﬁcant nucleotide
and amino acid differences between the two RVFV strains (Ken06
and SA01), separating them into distinct genetic clades in the
phylogenetic tree (Fig. 5). The observed variability in the level of
clinical and pathological responses in different sheep breeds sug-
gests potential breed inﬂuences on the clinical and pathological
outcome of RVFV infection. Future studies should be directed at
understanding the susceptibility of different US sheep breeds to
RVFV infection and the inﬂuence of the viral genotype on virus
virulence in natural hosts.
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Virus strains and cell culture
The RVFV Saudi Arabia 2001-1322 (SA01) (Miller et al., 2002)
and Kenya 2006-128b-15 (Ken06) (Sang et al., 2010) were used as
challenge isolates and were provided by R. Bowen, Colorado State
University through B. Miller, Centers for Disease Control, Fort
Collins, CO. The two virus strains were propagated in a C6/36 Aedes
albopictus cell line (ATCC, Manassas, VA) with MEM culture med-
ium (Life Technologies, Grand Island, NY) supplemented with 10%
fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO) and 1x
Penicillin/Streptomycin/Fungizone (PSF; Gibco, USA) and main-
tained at 28 °C in sealed ﬂasks; infected cells were maintained at
37 °C. The inocula were prepared from the ﬁrst passage. MP12 is a
non-virulent strain of RVFV, attenuated via chemical mutagenesis
(Caplen et al., 1985), and was used as the viral stock in plaque
reduction neutralization assays. For virus isolation and titration,
the Vero MARU (Middle America Research Unit, Panama) cell line
was used. Vero MARU cells were grown in Medium M-199
(M199E) culture medium (Sigma-Aldrich) supplemented with
10% FBS and 1xPSF, and maintained in a 37 °C, 5% CO2 incubator.
Animals and experimental design
Fourteen healthy 4–5 month old sheep (Dorper x Katahdin
cross), were obtained from a private breeder in Kansas, USA. None
of the sheep had prior exposure to RVFV infection. The animals
were acclimatized for seven days at the Large Animal Research
Center (LARC; Kansas State University) prior to relocation to a BSL-
3Ag facility at the Kansas State University Biosecurity Research
Institute. In BSL-3Ag, the animals were divided into two experi-
mental groups (n¼6 per group). Two animals served as mock
inoculation controls. The sheep were inoculated subcutaneously
with 2 ml of 1106 plaque forming units (PFU) of the Ken06 or
SA01 virus, or an equivalent volume of media, respectively. Post
inoculation, on days 0–10, 14 and 21 post infection (pi), all animals
were monitored daily for clinical signs including rectal tempera-
ture. Nasal swabs for virological analysis and blood samples for
virological, immunological, hematological and blood chemistry
analyses were collected. One sheep per experimental group was
euthanized and necropsied at 3, 4, 5, 6, 10 and 21 days post
infection (dpi). The two mock-inoculated control sheep were
necropsied at 21 dpi. Tissues were collected for viral titration and
histopathology. In a follow-up experiment, 5 Polypay sheep, aged
4–5 months, were each inoculated with 2106 PFU of Ken06
subcutaneously. Monitoring of clinical parameters (rectal tem-
peratures, viremia and tissue viral load) was performed from day
0 through day 10 pi; tissues for virus titration and histopathology
were also collected. Research was performed under an Institu-
tional Animal Care and Use Committee-approved protocol of
Kansas State University in compliance with the Animal Welfare Act
and other regulations relating to animals and experiments invol-
ving animals.
Virus titration
Tissue samples of liver, spleen and bile were collected at
necropsy and frozen at 80 °C. Approximately 10 mg of tissue was
added to 1 ml M199E supplemented with 10% fetal bovine serum
(FBS) and 1xpenicillin streptomycin fungizone (PSF), and homo-
genized by high-speed shaking dissociation with steel beads using
the TissueLyser instrument (QIAGEN Inc., Valencia, CA). Virus
challenge material, sheep sera, nasal swabs, bile and homogenized
tissue samples were titrated by standard plaque assay on Vero
MARU cells. Brieﬂy, conﬂuent cell monolayers were inoculatedwith ten-fold serially diluted samples in M199E and incubated for
1 h. Following adsorption, the inocula were replaced with a 1:1
mixture of 2% carboxymethyl cellulose (Sigma-Aldrich, St. Louis) in
2x M199E (20% FBS and 2xPSF) and returned to the incubator.
After 5 days, cells were ﬁxed and stained with crystal violet ﬁxa-
tive (25% formaldehyde, 10% ethanol, 5% acetic acid, 1% crystal
violet). Virus titers were calculated as plaque forming units per ml
(pfu/ml).
Viral RNA extraction and real-time RT-PCR
Total RNA from serum, nasal swabs or homogenated tissue
samples was extracted using TRIzol-LS reagent (Life Technologies,
Grand Island, NY) and the magnetic-bead capture MagMAX-96
total RNA Isolation kit (Life Technologies). Brieﬂy, 100 μl of aqu-
eous phase was added to 90 μl of isopropanol and 10 μl bead mix.
Total sample RNA was washed four times with wash buffer
(150 μl), then eluted in 30 μl of elution buffer. A published quad-
ruplex real-time reverse transcriptase-polymerase chain reaction
(RT-PCR) assay was used to detect each of the three RVFV RNA
genome segments (Wilson et al., 2013).
Viral RNA sequencing and phylogenetic analysis
To determine the genomic sequences of the two virus strains,
6 μl of viral RNA was reverse-transcribed using SuperScript III First-
Strand Synthesis SuperMix (Invitrogen, Carlsbad, CA) and ampliﬁed
using Platinum PCR SuperMix High Fidelity (Invitrogen, Carlsbad,
CA). The optimized cycle conditions for cDNA synthesis were 50 °C
for 70 min and 85 °C for 5 min and optimized cycle conditions for
PCR were 94 °C for 3 min, 45 cycles of 94 °C for 30 sec, 54 °C for 30 s
and 68 °C for 4 min followed by ﬁnal extension at 68 °C for 10 min.
All gene segments were ampliﬁed in two overlapping fragments
(primer sequences are available on request). The ampliﬁed PCR
products were then gel puriﬁed using QIAquick gel extraction kit
(Qiagen, Valencia, CA). All six ampliﬁed gene fragments were pooled
in equal copy number ratios and diluted to 0.2 ng/ml. One nanogram
of pooled DNA was used for sequencing library preparation using
the Illumina Nextera XT DNA library preparation kit (Illumina, San
Diego, CA). The pooled barcoded libraries were sequenced on an
Illumina MiSeq platform using paired 150 bp chemistry. Reads for
each sample were parsed into individual ﬁles based on barcoded
sequences. Parsed reads were loaded into CLC Genomic software
package (Qiagen, Valencia, CA). Reads were de novo assembled and
contigs were BLASTed against the Genbank nucleotide database.
Consensus sequence for each strain was obtained from contigs that
matched known Rift Valley fever virus genomes. For phylogenetic
analysis, nucleotide sequences of the M segment of different RVFV
strains were retrieved from GenBank (National Center for Bio-
technology Information, Bethesda, USA). These sequences were
aligned with the M segment nucleotide sequences of SA01 and
Ken06 using MegAlign (DNAStar Inc, Madison, USA) program by
method of ClustalW algorithm. A phylogenetic tree was constructed
applying the sequence alignment by neighbor-joining method using
the MegAlign software; and to infer tree robustness, 1000 bootstrap
replicates were computed.
RVFV serology
Anti-RVFV IgG antibody response
Anti-RVFV antibody response was measured by an anti-RVFV
total IgG indirect enzyme linked immunosorbent assay (ELISA)
using recombinant baculovirus expressed RVFV Gn and N proteins
as the diagnostic antigens as described previously (Faburay et al.,
2013; Fafetine et al., 2007; Paweska et al., 2008a). The cut-off point
for the speciﬁc ELISAs was determined by the addition of three
B. Faburay et al. / Virology 489 (2016) 128–140138standard deviations to the corresponding mean OD value of the
pre-vaccination serum. Mean OD values equal to or greater than
the cut-off value were considered positive seroconversion.
Plaque reduction neutralization test (PRNT80)
To assess anti-RVFV neutralizing antibody response to RVFV
infection, a plaque reduction neutralization test was performed as
previously described (Faburay et al., 2014). Brieﬂy, the stock of
MP12 RVFV was diluted to 50 PFU in 250 ml of 1x MEM containing
4% bovine serum albumin (Sigma-Aldrich, St. Louis, MO). Sepa-
rately, aliquots of serum from each vaccinated sheep were diluted
as follows: 1:10, 1:20, 1:40, 1:80, 1:160, 1:320, 1:640 and 1:1280 in
1x MEM containing 2% bovine serum albumin and 1% penicillin
streptomycin. Diluted serum (250 ml) was mixed with an equal
volume of diluted MP12 virus and incubated at 37 °C for 1 h.
Thereafter, each mixture of serum plus RVFV was used to infect
conﬂuent monolayers of Vero E6 cells in 12-well plates. After 1 h
adsorption at 37 °C and 5% CO2, the mixture was removed, and
1.5 ml of nutrient agarose overlay (1x MEM, 4% bovine serum
albumin and 0.9% SeaPlaque agar) was added to the monolayers.
After 4 days incubation, the cells were ﬁxed with 10% neutral
buffered formalin for 3 h prior to removal of the agarose overlay.
The monolayer was stained with 0.5% crystal violet in PBS, and
plaques were enumerated. The calculated PRNT80 corresponded to
the reciprocal titer of the highest serum dilution, which reduced
the number of plaques by 80% or more relative to the virus control.
As positive neutralizing serum control, a 1:40 dilution of day 28
neutralizing serum (titer41280) obtained from a sheep pre-
viously immunized with the RVFV glycoprotein subunit vaccine
was used (Faburay et al., 2014).
Hematology and blood chemistry analyses
Whole blood was added to K2 EDTA tubes (Becton- Dickinson,
Franklin Lakes, NJ) for complete blood count (CBC) determinations
using a VetScan HM5 Hematology Analyzer (Abaxis, Union City,
CA) according to the manufacturer’s instructions. Clinical blood
chemistry analyses examined the levels of albumin, alkaline
phosphatase (ALP), gamma-glutamyl transferase (GGT), aspartate
aminotransferase (AST) and blood urea nitrogen (BUN) in Lithium
heparinized blood on a VetScan VS2 Chemical Analyzer (Abaxis,
Union City, CA) according to manufacturer’s instructions. Normal
ranges for these chemistry values in sheep as speciﬁed by the
manufacturer were used as reference values.
Pathology
For the ﬁrst study in Dorper x Katahdin sheep, samples of the
following tissues were collected at necropsy and placed in 10%
neutral buffered formalin for at least 7 days: heart, lungs, trachea,
thymus, liver, gall bladder, spleen, pancreas, kidney, adrenal gland,
testicle, epididymis, salivary gland, thyroid gland, skeletal muscle
and skin from the inoculation site, urinary bladder, small and large
intestine, mesenteric lymph node, rumen, abomasum and eye. For
the sheep in the second study, liver, spleen, eye, kidney and
mesenteric lymph node were collected similarly.
For both studies, tissue samples were further trimmed, placed
in cassettes, dehydrated and embedded in parafﬁn. All histo-
chemical stains and immunohistochemistry were done on 5-mm
sections placed on positively charged slides. Hematoxylin-and-
eosin (H&E) stained tissues for the ﬁrst study were independently
reviewed by two veterinary pathologists in a blinded fashion and
the liver pathology scored for lesion severity on a semi-
quantitative scale from 0 to 3, where 0 signiﬁed no lesions and
1–3 progressively more severe pathology with a greater degree ofliver involvement. A detailed deﬁnition of this scale is outlined in
Table 3. Likewise the tissues were reviewed and liver lesions
similarly scored on the same scale for the 5 second study sheep.
Immunohistochemistry (IHC) for RVFV antigen using the
polyclonal rabbit anti-RVFV nucleocapsid protein antibody (Drolet
et al., 2012) was conducted on all liver and spleen selections as
well as additional tissue types where warranted by presence of
lesions. Brieﬂy, slides were deparafﬁnized and rehydrated, antigen
was retrieved in pH 9.0 EDTA buffer, Bond ER Solution 2 (Leica
Microsystems, Buffalo Grove, IL) for 10 min at 100 °C on the Leica
Bond-Max autostainer (Leica Microsystems), incubated ﬁrst for
15 min at RT with 1:1000 dilution of primary antibody and then
for 25 min at RT with Anti-rabbit Poly-HRP-IgG (Leica Micro-
systems) with intermediary Bond Wash Solution (Leica Micro-
systems) rinses. Thereafter slides were washed in deionized water,
blocked with 3% hydrogen peroxide diluted in water for 5 min,
visualized with Mixed 3,3'-diaminobenzidine (DAB) Reﬁne (Leica
Microsystems), then counterstained with hematoxylin, and
mounted in Acrymount (StatLab, McKinney, TX). Since samples
yielded unsightly background by the automated IHC technique, a
set of samples was additionally labeled by a different IHC detection
technique (Vestastain Elite ABC Kit, Vector Labs, Burlingame, CA).
Brieﬂy, slides were deparafﬁnized and rehydrated, antigen
retrieved using a vegetable steamer technique in pH 6.0 citrate
buffer with detergents (DAKO, Carpinteria, CA) for 20 min, blocked
with 3% hydrogen peroxide for 10 min, serum blocked as per kit,
incubated overnight at 4 °C with 1:1000 dilution of primary anti-
body, secondary antibody and ABC reagent applied as per kit, and
DAB followed by DAB Enhancing Solution applied as per vendor
instructions (Vector Labs), counterstained with hematoxylin, and
mounted in Permount (Electron Microscopy Systems, Hatﬁeld, PA).
Throughout, the following controls were employed, reagent con-
trol slides, with and without equivalent concentrations of primary
antibody matched animal serum and uninfected control animal
tissues. All gross tissue images were captured with a Canon G12
camera (Cannon, USA Inc, Melville, NY) and microscopic images
were captured with a DP25 camera (Olympus, Tokyo, Japan) on a
BX46 light microscope (Olympus) using CellSens Standard version
1.12 (Olympus). All microscopic images were further color cali-
brated using ChromaCal software ver 2.1 (Datacolor Inc., Law-
renceville, NJ) as per manufacturer's instructions and published
recommendations (Linden et al., 2015).
Statistical analysis
Differences in values of key experimental parameters were
analyzed statistically. Due to large variations in AST values among
animals owing to variable individual animal responses to experi-
mental inoculation, geometric mean values were derived for each
group at each time point. Also group or individual mean values for
temperature and BUN levels per time point were derived. The
values were analyzed by One-Way Analysis of Variance (ANOVA)
for independent samples followed by post hoc Tukey’s Honest
Signiﬁcant Difference test. Differences in neutralizing antibody
titers induced by the two wild type strains, Ken06 and SA01, were
determined by t-test for independent samples with the neu-
tralizing titer of 1280 considered highest; titers were tested for
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